Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis

Multiple Sclerosis Journal

Volumn 21, Issue 5, 2015, Pages 550-561

  Martínez, M Alba Mañé ^a   Olsson, Bob ^a   Bau, Laura ^b   Matas, Elisabet ^a   Calvo, Álvaro Cobo ^a   Andreasson, Ulf ^b   Blennow, Kaj ^a   Romero Pinel, Lucia ^a   Martínez Yélamos, Sergio ^a   Zetterberg, Henrik ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Biomarkers; cerebrospinal fluid; chitinase 3 like 1 protein; diagnostics; disability progression; glial fibrillary acidic protein; multiple sclerosis; neurofilament light protein; prognostic markers

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN 38; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; BIOLOGICAL MARKER; CHITINASE 3 LIKE 1 PROTEIN; GLIAL FIBRILLARY ACIDIC PROTEIN; MEMBRANE PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUROFILAMENT LIGHT PROTEIN; PROTEIN S100B; T TAU PROTEIN; UNCLASSIFIED DRUG; ALPHA CLEAVED SOLUBLE AMYLOID PRECURSOR PROTEIN; BETA CLEAVED SOLUBLE AMYLOID PRECURSOR PROTEIN; GLIAL BIOLOGICAL MARKER; NEURONAL BIOLOGICAL MARKER; P TAU PROTEIN; TAU PROTEIN;

ADULT; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROSPINAL FLUID ANALYSIS; CLINICALLY DEFINITE MULTIPLE SCLEROSIS; DEMYELINATING DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; CEREBROSPINAL FLUID; DISABILITY; GLIA; METABOLISM; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NERVE CELL; ONSET AGE; PROGNOSIS; RECURRENT DISEASE; CONTROLLED STUDY; DISABILITY PROGRESSION; DISEASE DURATION; FALSE NEGATIVE RESULT; GENERAL ASPECTS OF DISEASE; MYELITIS; OPTIC NEURITIS; PREDICTIVE VALUE; RELAPSE; REMISSION; SEX RATIO; TIME SERIES ANALYSIS;

ADULT; AGE OF ONSET; BIOMARKERS; DISABILITY EVALUATION; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NEUROGLIA; NEURONS; PROGNOSIS; RECURRENCE;

EID: 84964695041     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458514549397     Document Type: Article

References (29)

1. Barkhof F, Calabresi PA, Miller DH, et al. Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat Rev Neurol. 2009 ; 5: 256-266
2. Frischer JM, Bramow S, Dal-Bianco A, et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain. 2009 ; 132: 1175-1189
3. Eng LF, Ghirnikar RS. GFAP and astrogliosis. Brain Pathol. 1994 ; 4: 229-237
4. Bonneh-Barkay D, Wang G, Starkey A, et al. In vivo CHI3L1 (YKL-40) expression in astrocytes in acute and chronic neurological diseases. J Neuroinflam. 2010 ; 7: 34
5. Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med. 1998 ; 338: 278-285
6. Filippi M, Bozzali M, Rovaris M, et al. Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain. 2003 ; 126: 433-437
7. Popescu BF, Lucchinetti CF. Pathology of demyelinating diseases. Annu Rev Pathol. 2012 ; 7: 185-217
8. Van der Voorn P, Tekstra J, Beelen RH, et al. Expression of MCP-1 by reactive astrocytes in demyelinating multiple sclerosis lesions. Am J Pathol. 1999 ; 154: 45-51
9. Czeh M, Gressens P, Kaindl AM. The yin and yang of microglia. Dev Neurosci. 2011 ; 33: 199-209
10. Eng LF, Vanderhaeghen JJ, Bignami A, et al. An acidic protein isolated from fibrous astrocytes. Brain Res. 1971 ; 28: 351-354
11. Lassmann H, Brück W, Lucchinetti CF. The immunopathology of multiple sclerosis: An overview. Brain Pathol. 2007 ; 17: 210-218
12. Trapp BD, Nave KA. Multiple sclerosis: An immune or neurodegenerative disorder?. Ann Rev Neurosci. 2008 ; 31: 247-269
13. Binder LI, Frankfurter A, Rebhun LI. The distribution of Tau in the mammalian central nervous system. J Cell Biol. 1985 ; 101: 1371-1378
14. Donato R. S100: A multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol. 2001 ; 33: 637-638
15. Gehrmann J, Banati RB, Cuzner ML, et al. Amyloid precursor protein (APP) expression in multiple sclerosis lesions. Glia. 1995 ; 15: 141-151
16. Ferguson B, Matyszak MK, Esiri MM, et al. Axonal damage in acute multiple sclerosis lesions. Brain. 1997 ; 120: 393-399
17. Confavreux C, Compston DAS, Hommes OR, et al. EDMUS, a European database for multiple sclerosis. J Neurol Neurosurg Psychiatry. 1992 ; 55: 671-676
18. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol. 1983 ; 13: 227-231
19. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol. 2001 ; 50: 121-127
20. Polman CH, Wolinsky JS, Reingold SC. Multiple sclerosis diagnostic criteria: Three years later. Mult Scler. 2005 ; 11: 5-12
21. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An Expanded Disability Status Scale (EDSS). Neurology. 1983 ; 33: 1444-1452
22. Norgren N, Rosengren L, Stigbrand T. Elevated neurofilament levels in neurological diseases. Brain Res. 2003 ; 987: 25-31
23. Rosengren LE, Wikkelso C, Hagberg L. A sensitive ELISA for glial fibrillary acidic protein: Application in CSF of adults. J Neurosci Methods. 1994 ; 51: 197-204
24. Teunissen CE, Iacobaeus E, Khademi M, et al. Combination of N-Acetylaspartate and neurofilaments in multiple sclerosis. Neurology. 2009 ; 72: 1322-1329
25. Comabella M, Fernández M, Martin R, et al. Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. Brain. 2010 ; 133: 1082-1093
26. Malmeström C, Haghighi S, Rosengren L, et al. Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. Neurology. 2003 ; 23: 1720-1725
27. Axelsson M, Malmeström C, Nilsson S, et al. Glial fibrillary acidic protein: A potential biomarker for progression in multiple sclerosis. J Neurol. 2011 ; 258: 882-888
28. Kuhle J, Plattner K, Bestwick JP, et al. A comparative study of CSF neurofilament light and heavy chain protein in MS. Mult Scler. 2013 ; 19: 1597-1603
29. Matsushita T, Tateishi T, Isobe N, et al. Characteristic cerebrospinal fluid cytokine/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis. PLoS One. 2013 ; 18: e61835